Biocept Inc (BIOC) 0.66 $BIOC
Biocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test
PR Newswire - Tue May 31, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces the expansion of its liquid biopsy offering into immuno-oncology with the commercial launch of its PD-L1 protein expression test. The CLIA-validated test uses Biocept's proprietary, patented Target Selector(TM) platform with circulating tumor cells (CTCs) from a patient's blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient's cancer therapy. The PD-L1 test was developed by Biocept's scientists in collaboration with David Rimm, MD, PhD, Professor of Pathology and Medicine at Yale University School of Medicine and a scientific advisor to Biocept.
BIOC: 0.66 (-0.04)
High Sensitivity of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured in Two Abstracts at ASCO
PR Newswire - Wed May 25, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces that study data building additional support for the clinical utility of its Target Selector(TM) liquid biopsy offerings is being featured in two abstracts at the 2016 American Society of Clinical Oncology (ASCO) Meeting being held June 3-7 in Chicago.
BIOC: 0.66 (-0.04)
Biocept Announces Master Services Agreement with Pharma Company to Develop Liquid Biopsy Tests
PR Newswire - Mon May 23, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with liquid biopsy technology for cancer profiling and monitoring, announces that it has entered into a master services agreement with a biopharmaceutical company to develop targeted liquid biopsy tests for multiple tumor types and molecular targets. The agreement includes utilizing Biocept's patented, proprietary Target Selector(TM) platforms to develop assays with both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).
BIOC: 0.66 (-0.04)
Biocept Launches Proprietary Liquid Biopsy Test to Detect RET Fusions in Patients with Lung Cancer
PR Newswire - Thu May 19, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with liquid biopsy technology for cancer profiling and monitoring, announces the launch of its test to detect RET oncogene fusions from a simple blood draw. Positive identification of patients with the RET gene provides important information in determining therapy options including targeted tyrosine kinase inhibitors.
BIOC: 0.66 (-0.04)
Biocept Reports 2016 First Quarter Financial Results
PR Newswire - Thu May 12, 3:05PM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the diagnosis and treatment of cancer, reports financial results for the quarter ended March 31, 2016, and provides an update on business progress.
BIOC: 0.66 (-0.04)
Biocept Expands Intellectual Property Portfolio with 12th Granted Patent on its Key Liquid Biopsy Technology
PR Newswire - Thu May 12, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces the award of a patent by the U.S. Patent and Trademark Office covering the use of a novel stain in the detection of rare cells such as circulating tumor cells (CTCs) from blood and other biological fluids. U.S. Patent 9,347,946 entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION will publish on May 24, 2016.
BIOC: 0.66 (-0.04)
Biocept to Hold 2016 First Quarter Conference Call on May 12
PR Newswire - Thu May 05, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with a commercialized liquid biopsy technology, Target SelectorTM, focused on cancer treatment and monitoring, announces that it will release financial results for the three months ended March 31, 2016 after market close on Thursday, May 12, 2016. Biocept management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
BIOC: 0.66 (-0.04)
Biocept Inc. Announces Proposed Public Offering Of Common Stock And Warrants
PR Newswire - Thu Apr 28, 3:53PM CDT
Biocept, Inc. ("Biocept"
(Nasdaq: BIOC) today announced a proposed registered public offering of its common stock and warrants, subject to market and other conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
BIOC: 0.66 (-0.04)
Biocept Collaborates with MedStar Georgetown University Hospital for Liquid Biopsy Study
PR Newswire - Wed Apr 27, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with a commercial liquid biopsy technology focused on cancer treatment and monitoring, announces the initiation of a collaborative study with MedStar Georgetown University Hospital to evaluate resistance biomarkers in patients diagnosed with non-small cell lung cancer (NSCLC) who are currently being treated with EGFR inhibitors or chemotherapy. Tumors from patients with advanced NSCLC are routinely screened for the presence of EGFR mutations, with these mutations occurring in approximately 10 to 20 percent of NSCLC patients.
BIOC: 0.66 (-0.04)
Biocept Continues International Expansion through Agreement with Quest Diagnostics Mexico
PR Newswire - Mon Apr 18, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC) continues to expand internationally by announcing that its Target Selector(TM) industry-leading blood-based test to detect EGFR mutations associated with lung cancer will now be accessible to patients in Mexico through a reference agreement with Quest Diagnostics Mexico. Terms of the transaction were not disclosed. Biocept is a leading molecular diagnostics company that commercializes and develops liquid biopsy tests for cancer profiling and monitoring.
BIOC: 0.66 (-0.04)
Biocept Forms Clinical Advisory Board of World-Renowned Oncologists
PR Newswire - Wed Mar 30, 6:00AM CDT
More than 1.5 million new cancer cases are expected to be diagnosed in 2016, according to the American Cancer Society. To further its mission of improving outcomes for the millions of people who battle cancer each year, Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with proven liquid biopsy technology for cancer profiling and monitoring, announces the formation of a Clinical Advisory Board. The Clinical Advisory Board is comprised of leading oncologists with diverse specialties to provide guidance on expanding Biocept's physician customer base and support useage of Biocept's liquid biopsy tests.
BIOC: 0.66 (-0.04)
Biocept's Mark Foletta Honored with CFO Lifetime Achievement Award
PR Newswire - Wed Mar 23, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that Interim Chief Financial Officer Mark Foletta has received the CFO Lifetime Achievement Award from the San Diego Business Journal in recognition of his "deep and rich career guiding the financial success of multiple companies."
BIOC: 0.66 (-0.04)
Biocept to Collaborate on Biopharma Company Clinical Trial by Identifying Biomarkers Found in Cerebral Spinal Fluid for Patients with Lung Cancer that has Spread to the Brain
PR Newswire - Mon Mar 21, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces a collaboration on a biopharmaceutical company clinical trial analyzing biomarkers using both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF). The trial is being conducted in patients with non-small cell lung cancer (NSCLC) whose disease has spread to the brain or membranes surrounding the brain and spinal cord, known as leptomeningeal disease.
BIOC: 0.66 (-0.04)
Progenetics to Distribute Biocept's Liquid Biopsy Assays in Israel
PR Newswire - Thu Mar 10, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that Progenetics LTD will market and distribute Biocept's complete portfolio of Target Selector(TM) liquid biopsy assays in Israel. Terms of the transaction were not disclosed.
BIOC: 0.66 (-0.04)
Biocept Secures Agreement with FedMed
PR Newswire - Wed Mar 09, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, announces an agreement with preferred provider organization (PPO) network FedMed. FedMed members now have improved network access to Biocept's proprietary Target Selector(TM) liquid biopsy testing.
BIOC: 0.66 (-0.04)
Biocept to Present at the 28th Annual ROTH Conference
PR Newswire - Mon Mar 07, 7:30AM CST
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at the 28th Annual ROTH Conference on Monday, March 14, 2016, at 8:30 a.m. Pacific time (11:30 a.m. Eastern time). The conference is being held at The Ritz Carlton Laguna Niguel hotel in Dana Point, Calif.
BIOC: 0.66 (-0.04)
Biocept to Present at Upcoming Investment Conferences
PR Newswire - Tue Feb 02, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at two upcoming conferences:
BIOC: 0.66 (-0.04)
Biocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference
PR Newswire - Mon Jan 25, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall will speak at today's "Clinical Testing Applications of Liquid Biopsy" session at the Personalized Medicine World Conference (PMWC) 2016. The conference is being held in Mountain View, Calif.
BIOC: 0.66 (-0.04)
Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois
PR Newswire - Tue Jan 12, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that it has entered into an agreement with Blue Cross Blue Shield of Illinois (BCBS IL) allowing its members access to Biocept's broad menu for liquid biopsy testing. With the addition of BCBS IL's more than eight million members, the number of patients with access to Biocept's liquid biopsy assays through their healthcare insurance plan has increased to approximately 133 million.
BIOC: 0.66 (-0.04)
Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer
PR Newswire - Thu Jan 07, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient's blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.
BIOC: 0.66 (-0.04)
Biocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test
PR Newswire - Tue May 31, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces the expansion of its liquid biopsy offering into immuno-oncology with the commercial launch of its PD-L1 protein expression test. The CLIA-validated test uses Biocept's proprietary, patented Target Selector(TM) platform with circulating tumor cells (CTCs) from a patient's blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient's cancer therapy. The PD-L1 test was developed by Biocept's scientists in collaboration with David Rimm, MD, PhD, Professor of Pathology and Medicine at Yale University School of Medicine and a scientific advisor to Biocept.
BIOC: 0.66 (-0.04)
High Sensitivity of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured in Two Abstracts at ASCO
PR Newswire - Wed May 25, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces that study data building additional support for the clinical utility of its Target Selector(TM) liquid biopsy offerings is being featured in two abstracts at the 2016 American Society of Clinical Oncology (ASCO) Meeting being held June 3-7 in Chicago.
BIOC: 0.66 (-0.04)
Biocept Announces Master Services Agreement with Pharma Company to Develop Liquid Biopsy Tests
PR Newswire - Mon May 23, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with liquid biopsy technology for cancer profiling and monitoring, announces that it has entered into a master services agreement with a biopharmaceutical company to develop targeted liquid biopsy tests for multiple tumor types and molecular targets. The agreement includes utilizing Biocept's patented, proprietary Target Selector(TM) platforms to develop assays with both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).
BIOC: 0.66 (-0.04)
Biocept Launches Proprietary Liquid Biopsy Test to Detect RET Fusions in Patients with Lung Cancer
PR Newswire - Thu May 19, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with liquid biopsy technology for cancer profiling and monitoring, announces the launch of its test to detect RET oncogene fusions from a simple blood draw. Positive identification of patients with the RET gene provides important information in determining therapy options including targeted tyrosine kinase inhibitors.
BIOC: 0.66 (-0.04)
Biocept Reports 2016 First Quarter Financial Results
PR Newswire - Thu May 12, 3:05PM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the diagnosis and treatment of cancer, reports financial results for the quarter ended March 31, 2016, and provides an update on business progress.
BIOC: 0.66 (-0.04)
Biocept Expands Intellectual Property Portfolio with 12th Granted Patent on its Key Liquid Biopsy Technology
PR Newswire - Thu May 12, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces the award of a patent by the U.S. Patent and Trademark Office covering the use of a novel stain in the detection of rare cells such as circulating tumor cells (CTCs) from blood and other biological fluids. U.S. Patent 9,347,946 entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION will publish on May 24, 2016.
BIOC: 0.66 (-0.04)
Biocept to Hold 2016 First Quarter Conference Call on May 12
PR Newswire - Thu May 05, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with a commercialized liquid biopsy technology, Target SelectorTM, focused on cancer treatment and monitoring, announces that it will release financial results for the three months ended March 31, 2016 after market close on Thursday, May 12, 2016. Biocept management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
BIOC: 0.66 (-0.04)
Biocept Inc. Announces Proposed Public Offering Of Common Stock And Warrants
PR Newswire - Thu Apr 28, 3:53PM CDT
Biocept, Inc. ("Biocept"
(Nasdaq: BIOC) today announced a proposed registered public offering of its common stock and warrants, subject to market and other conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BIOC: 0.66 (-0.04)
Biocept Collaborates with MedStar Georgetown University Hospital for Liquid Biopsy Study
PR Newswire - Wed Apr 27, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with a commercial liquid biopsy technology focused on cancer treatment and monitoring, announces the initiation of a collaborative study with MedStar Georgetown University Hospital to evaluate resistance biomarkers in patients diagnosed with non-small cell lung cancer (NSCLC) who are currently being treated with EGFR inhibitors or chemotherapy. Tumors from patients with advanced NSCLC are routinely screened for the presence of EGFR mutations, with these mutations occurring in approximately 10 to 20 percent of NSCLC patients.
BIOC: 0.66 (-0.04)
Biocept Continues International Expansion through Agreement with Quest Diagnostics Mexico
PR Newswire - Mon Apr 18, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC) continues to expand internationally by announcing that its Target Selector(TM) industry-leading blood-based test to detect EGFR mutations associated with lung cancer will now be accessible to patients in Mexico through a reference agreement with Quest Diagnostics Mexico. Terms of the transaction were not disclosed. Biocept is a leading molecular diagnostics company that commercializes and develops liquid biopsy tests for cancer profiling and monitoring.
BIOC: 0.66 (-0.04)
Biocept Forms Clinical Advisory Board of World-Renowned Oncologists
PR Newswire - Wed Mar 30, 6:00AM CDT
More than 1.5 million new cancer cases are expected to be diagnosed in 2016, according to the American Cancer Society. To further its mission of improving outcomes for the millions of people who battle cancer each year, Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with proven liquid biopsy technology for cancer profiling and monitoring, announces the formation of a Clinical Advisory Board. The Clinical Advisory Board is comprised of leading oncologists with diverse specialties to provide guidance on expanding Biocept's physician customer base and support useage of Biocept's liquid biopsy tests.
BIOC: 0.66 (-0.04)
Biocept's Mark Foletta Honored with CFO Lifetime Achievement Award
PR Newswire - Wed Mar 23, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that Interim Chief Financial Officer Mark Foletta has received the CFO Lifetime Achievement Award from the San Diego Business Journal in recognition of his "deep and rich career guiding the financial success of multiple companies."
BIOC: 0.66 (-0.04)
Biocept to Collaborate on Biopharma Company Clinical Trial by Identifying Biomarkers Found in Cerebral Spinal Fluid for Patients with Lung Cancer that has Spread to the Brain
PR Newswire - Mon Mar 21, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces a collaboration on a biopharmaceutical company clinical trial analyzing biomarkers using both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF). The trial is being conducted in patients with non-small cell lung cancer (NSCLC) whose disease has spread to the brain or membranes surrounding the brain and spinal cord, known as leptomeningeal disease.
BIOC: 0.66 (-0.04)
Progenetics to Distribute Biocept's Liquid Biopsy Assays in Israel
PR Newswire - Thu Mar 10, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that Progenetics LTD will market and distribute Biocept's complete portfolio of Target Selector(TM) liquid biopsy assays in Israel. Terms of the transaction were not disclosed.
BIOC: 0.66 (-0.04)
Biocept Secures Agreement with FedMed
PR Newswire - Wed Mar 09, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, announces an agreement with preferred provider organization (PPO) network FedMed. FedMed members now have improved network access to Biocept's proprietary Target Selector(TM) liquid biopsy testing.
BIOC: 0.66 (-0.04)
Biocept to Present at the 28th Annual ROTH Conference
PR Newswire - Mon Mar 07, 7:30AM CST
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at the 28th Annual ROTH Conference on Monday, March 14, 2016, at 8:30 a.m. Pacific time (11:30 a.m. Eastern time). The conference is being held at The Ritz Carlton Laguna Niguel hotel in Dana Point, Calif.
BIOC: 0.66 (-0.04)
Biocept to Present at Upcoming Investment Conferences
PR Newswire - Tue Feb 02, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at two upcoming conferences:
BIOC: 0.66 (-0.04)
Biocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference
PR Newswire - Mon Jan 25, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall will speak at today's "Clinical Testing Applications of Liquid Biopsy" session at the Personalized Medicine World Conference (PMWC) 2016. The conference is being held in Mountain View, Calif.
BIOC: 0.66 (-0.04)
Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois
PR Newswire - Tue Jan 12, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that it has entered into an agreement with Blue Cross Blue Shield of Illinois (BCBS IL) allowing its members access to Biocept's broad menu for liquid biopsy testing. With the addition of BCBS IL's more than eight million members, the number of patients with access to Biocept's liquid biopsy assays through their healthcare insurance plan has increased to approximately 133 million.
BIOC: 0.66 (-0.04)
Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer
PR Newswire - Thu Jan 07, 6:00AM CST
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient's blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.
BIOC: 0.66 (-0.04)
